EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.

Auteurs

Menis J, Greiller L, Demontrond P, Monnet I, Novello S, Livi L, Young R, Decroisette C, Cloarec N, Robinet G, Schott R, Fayette J, Banna GL, De Marinis F, Califano R, Duchemann B, Luciani A, Colantonio I, Fournier B, Pretzenbacher Y, Caramella C, Silva M, Berghmans T, Dingemans AM, Bironzo P, Tugwood J, Zhou C, Hill S, Bradbury K, Morris K, Kilgour E, Dive C, Blackhall F, Besse B

  • Date de publication

    October 2025
  • Type

    Article
  • Review

    Eur J Cancer
  • Researcher's name

    BERGHMANS THIERRY
  • Hôpital

    Institut Jules Bordet
  • Service

    Médecine Interne, Médecine Oncologique
  • PMID

    41192233
  • DOI

    10.1016/j.ejca.2025.116059